We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why Adma Biologics (ADMA) Fell More Than Broader Market
Read MoreHide Full Article
Adma Biologics (ADMA - Free Report) ended the recent trading session at $14.56, demonstrating a -3.51% change from the preceding day's closing price. The stock's change was less than the S&P 500's daily loss of 0.63%. Elsewhere, the Dow lost 0.65%, while the tech-heavy Nasdaq lost 0.47%.
The infectious disease drug developer's shares have seen a decrease of 3.02% over the last month, not keeping up with the Medical sector's gain of 3.09% and the S&P 500's gain of 0.92%.
Investors will be eagerly watching for the performance of Adma Biologics in its upcoming earnings disclosure. The company's upcoming EPS is projected at $0.16, signifying a 6.67% increase compared to the same quarter of the previous year. Simultaneously, our latest consensus estimate expects the revenue to be $130.1 million, showing a 8.56% escalation compared to the year-ago quarter.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $0.57 per share and revenue of $506.7 million, indicating changes of +16.33% and +18.82%, respectively, compared to the previous year.
Investors should also pay attention to any latest changes in analyst estimates for Adma Biologics. These revisions help to show the ever-changing nature of near-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has remained steady. At present, Adma Biologics boasts a Zacks Rank of #3 (Hold).
In the context of valuation, Adma Biologics is at present trading with a Forward P/E ratio of 26.47. This signifies a premium in comparison to the average Forward P/E of 19.89 for its industry.
The Medical - Biomedical and Genetics industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 84, positioning it in the top 35% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Here's Why Adma Biologics (ADMA) Fell More Than Broader Market
Adma Biologics (ADMA - Free Report) ended the recent trading session at $14.56, demonstrating a -3.51% change from the preceding day's closing price. The stock's change was less than the S&P 500's daily loss of 0.63%. Elsewhere, the Dow lost 0.65%, while the tech-heavy Nasdaq lost 0.47%.
The infectious disease drug developer's shares have seen a decrease of 3.02% over the last month, not keeping up with the Medical sector's gain of 3.09% and the S&P 500's gain of 0.92%.
Investors will be eagerly watching for the performance of Adma Biologics in its upcoming earnings disclosure. The company's upcoming EPS is projected at $0.16, signifying a 6.67% increase compared to the same quarter of the previous year. Simultaneously, our latest consensus estimate expects the revenue to be $130.1 million, showing a 8.56% escalation compared to the year-ago quarter.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $0.57 per share and revenue of $506.7 million, indicating changes of +16.33% and +18.82%, respectively, compared to the previous year.
Investors should also pay attention to any latest changes in analyst estimates for Adma Biologics. These revisions help to show the ever-changing nature of near-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has remained steady. At present, Adma Biologics boasts a Zacks Rank of #3 (Hold).
In the context of valuation, Adma Biologics is at present trading with a Forward P/E ratio of 26.47. This signifies a premium in comparison to the average Forward P/E of 19.89 for its industry.
The Medical - Biomedical and Genetics industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 84, positioning it in the top 35% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.